My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
06/15/2021
CBCC
>
Meetings
>
2020's
>
2021
>
06/15/2021
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
8/26/2021 2:01:46 PM
Creation date
8/26/2021 1:57:21 PM
Metadata
Fields
Template:
Meetings
Meeting Type
BCC Regular Meeting
Document Type
Agenda Packet
Meeting Date
06/15/2021
Meeting Body
Board of County Commissioners
Jump to thumbnail
< previous set
next set >
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
258
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
Support opioid abatement research that may include, but is not limited to, the following: <br />1. Monitoring, surveillance, data collection, and evaluation of programs and strategies described in this <br />opioid abatement strategy list. <br />2. Research non -opioid treatment of chronic pain. <br />3. Research on improved service delivery for modalities such as SBIRT that demonstrate promising but <br />mixed results in populations vulnerable to opioid use disorders. <br />4. Research on novel harm reduction and prevention efforts such as the provision of fentanyl test strips. <br />5. Research on innovative supply-side enforcement efforts such as improved detection of mail -based <br />delivery of synthetic opioids. <br />6. Expanded research on swift/certain/fair models to reduce and deter opioid misuse within criminal <br />justice populations that build upon promising approaches used to address other substances (e.g. Hawaii <br />HOPE and Dakota 24/7). <br />7. Epidemiological surveillance of OUD-related behaviors in critical populations including individuals <br />entering the criminal justice system, including but not limited to approaches modeled on the Arrestee <br />Drug Abuse Monitoring (ADAM) system. <br />8. Qualitative and quantitative research regarding public health risks and harm reduction opportunities <br />within illicit drug markets, including surveys of market participants who sell or distribute illicit opioids. <br />9. Geospatial analysis of access barriers to MAT and their association with treatment engagement and <br />treatment outcomes. <br />79 <br />
The URL can be used to link to this page
Your browser does not support the video tag.